(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 2.46% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.34%.
Castle Biosciences's revenue in 2025 is $343,530,000.On average, 10 Wall Street analysts forecast CSTL's revenue for 2025 to be $9,856,426,371, with the lowest CSTL revenue forecast at $9,094,602,371, and the highest CSTL revenue forecast at $10,245,803,082. On average, 10 Wall Street analysts forecast CSTL's revenue for 2026 to be $9,767,400,961, with the lowest CSTL revenue forecast at $9,145,098,751, and the highest CSTL revenue forecast at $10,205,814,619.
In 2027, CSTL is forecast to generate $11,100,447,018 in revenue, with the lowest revenue forecast at $10,240,549,124 and the highest revenue forecast at $11,790,466,916.